Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia

Clinical Infectious Diseases

Volumn 59, Issue 1, 2014, Pages 62-70

  Karhu, J ^a   Ala Kokko, T I ^a   Vuorinen, T ^d   Ohtonen, P ^b   Syrjala H ^c  

^a Division of Intensive Care   (Finland)

^b Department of Anaesthesiology and Surgery ^*  (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

etiology; intensive care; severe community acquired pneumonia; viral infection

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADENOVIRUS; ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD CULTURE; BRONCHIAL ASPIRATION PROCEDURE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; LOWER RESPIRATORY TRACT; MALE; MICROBIOLOGICAL EXAMINATION; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOPLASMA PNEUMONIAE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY VIRUS; RHINOVIRUS; SEVERE COMMUNITY ACQUIRED PNEUMONIA; URINALYSIS; VENTILATED PATIENT; VIRUS ETIOLOGY; AGED; ARTIFICIAL VENTILATION; CLASSIFICATION; COHORT ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PNEUMONIA, VIRAL; VERY ELDERLY; VIROLOGY; VIRUS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PNEUMONIA, VIRAL; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RESPIRATION, ARTIFICIAL; VIRUSES; YOUNG ADULT;

EID: 84904015388     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu237     Document Type: Article

References (40)

1. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-23.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27-72.
3. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 377:1264-75.
4. Templeton KE, Scheltinga SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Claas EC. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41:345-51.
5. Bibby DF, McElarney I, Breuer J, Clark DA. Comparative evaluation of the Seegene Seeplex RV15 and real-time PCR for respiratory virus detection. J Med Virol 2011; 83:1469-75.
6. de Roux A, Marcos MA, Garcia E, et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004; 125:1343-51.
7. Angeles Marcos M, Camps M, Pumarola T, et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther 2006; 11:351-9.
8. Saito A, Kohno S, Matsushima T, et al.; Study Group. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother 2006; 12:63-9.
9. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134:1141-8.
10. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42-8.
11. Diaz A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007; 131:779-87.
12. Charles PG, Whitby M, Fuller AJ, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46:1513-21.
13. Hohenthal U, Vainionpää R, Meurman O, et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. Scand J Infect Dis 2008; 40:131-8.
14. Hohenthal U, Vainionpaa R, Nikoskelainen J, Kotilainen P. The role of rhinoviruses and enteroviruses in community acquired pneumonia in adults. Thorax 2008; 63:658-9.
15. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202-9.
16. Choi SH, Hong SB, Ko GB, et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012; 186:325-32.
17. Wiemken T, Peyran P, Bryant K, et al. Incidence of respiratory viruses in patients with community-acquired pneumonia admitted to the intensive care unit; results from Severe Influenza Pneumonia Surveillance (SIPS) project. Eur J Clin Microbiol Infect Dis 2013; 32:705-10.
18. Luchsinger V, Ruiz M, Zunino E, et al. Community-acquired pneumonia in Chile: the clinical relevance in the detection of viruses and atypical bacteria. Thorax 2013; 68:1000-6.
19. Levy MM, Fink MP, Marshall JC, et al. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31:1250-6.
20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
21. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63.
22. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-10.
23. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
24. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-82.
25. Peltola V, Waris M, Österback R, Susi P, Ruuskanen O, Hyypiä T. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections. J Infect Dis 2008; 197:382-9.
26. de la Tabla VO, Masia M, Antequera P, et al. Comparison of combined nose-throat swabs with nasopharyngeal aspirates for detection of pandemic influenza A/H1N1 2009 virus by real-time reverse transcriptase PCR. J Clin Microbiol 2010; 48:3492-5.
27. Lopez Roa P, Rodriguez-Sanchez B, Catalan P, et al. Diagnosis of influenza in intensive care units: lower respiratory tract samples are better than nose-throat swabs. Am J Respir Crit Care Med 2012; 186:929-30.
28. Puchhammer-Stöckl E. Detection of human cytomegalovirus in bronchoalveolar lavage fluid of lung transplant recipients reflects local virus replication and not contamination from the throat. J Clin Microbiol 2010; 48:4273-4.
29. Jouneau S, Poineuf JS, Minjolle S, et al. Which patients should be tested for viruses on bronchoalveolar lavage fluid? Eur J Clin Microbiol Infect Dis 2013; 32:671-7.
30. Magnusson J, Westin J, Andersson LM, Brittain-Long R, Riise GC. The impact of viral respiratory tract infections on long-term morbidity and mortality following lung transplantation: a retrospective cohort study using a multiplex PCR panel. Transplantation 2013; 95:383-8.
31. Seki M, Kosai K, Yanagihara K, et al. Disease severity in patients with simultaneous influenza and bacterial pneumonia. Intern Med 2007; 46:953-8.
32. Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009; 4:e8540.
33. Cillóniz C, Ewig S, Ferrer M, et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care 2011; 15:R209.
34. Jamieson AM, Pasman L, Yu S, et al. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 2013; 340:1230-4.
35. Falsey A, Becker KL, Swinburne AJ, et al. Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. JID 2013; 208:432-41.
36. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171:1322-31.
37. Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J 2011; 30:289-94.
38. Morfin F, Dupuis-Girod S, Frobert E, et al. Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone. Antivir Ther 2009; 14:55-61.
39. Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. Crit Care Med 2010; 38(suppl):e43-51.
40. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.